Apogem Capital LLC Galapagos Nv Transaction History

Apogem Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$42.27 - $57.6 $37,324 - $50,860	883 Added 3.19%	28,584 $1.22 Million
Q2 2022 Aug 15, 2022	BUY	$52.3 - $71.59 $5,125 - $7,015	98 Added 0.36%	27,701 $1.55 Million
Q1 2022 May 16, 2022	BUY	$51.32 - $68.5 $83,395 - $111,312	1,625 Added 6.26%	27,603 $1.71 Million
Q4 2021 Feb 14, 2022	BUY	$47.03 - $57.12 $315,618 - $383,332	6,711 Added 34.83%	25,978 $1.43 Million
Q3 2021 Nov 15, 2021	BUY	$52.17 - $70.2 $716,502 - $964,126	13,734 Added 248.22%	19,267 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$68.86 - $83.34 $29,058 - $35,169	422 Added 8.26%	5,533 $381,000
Q1 2021 May 14, 2021	BUY	$76.15 - $111.94 $389,202 - $572,125	5,111 New	5,111 $394,000

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Apogem Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Apogem Capital LLC with notifications on news.